In the third quarter, Banyan Capital Management acquired 3,853 shares of Johnson & Johnson, representing approximately $714,000 in market value and accounting for 0.3% of the firm’s overall holdings, making it Banyan’s 22nd largest position. This entry follows substantial stakes taken earlier by Norges Bank, which deployed nearly $4.9 billion for a new position in the second quarter, and by Laurel Wealth Advisors, which expanded its holding by over 15,000% to 7.42 million shares valued at $1.13 billion. Vanguard Group added 3.085 million shares in the quarter, bringing its total to 237 million shares worth more than $36.2 billion, while Geode Capital and Legal & General Group boosted their stakes by 2.1% and 6.2%, respectively. Overall, institutional ownership stands at 69.6%, underscoring strong confidence in the company’s multi‐segment healthcare portfolio.

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for the combination therapy AKEEGA (niraparib plus abiraterone) targeting BRCA1/2‐mutant metastatic hormone‐sensitive prostate cancer. This recommendation, if adopted by the European Commission, would mark Johnson & Johnson’s first major new oncology approval in this indication, potentially unlocking a multi‐hundred‐million‐dollar revenue stream and accelerating the pharmaceuticals division’s projected mid‐single‐digit growth rate.

Several major brokerages have revised their outlooks following the company’s latest quarterly report. Daiwa Capital Markets retained an Outperform rating while raising its target to $237, Morgan Stanley upgraded to Overweight on a strengthened growth forecast, and Scotiabank reiterated its Outperform stance with a newly set target of $265. Loop Capital initiated coverage with a $220 objective, RBC raised its target to $240, and Goldman Sachs upheld its Buy rating at $250. The consensus among 26 analysts now leans Moderate Buy with an average target near $233, reflecting a blend of bullish enthusiasm and measured optimism.

In the quarter ended January 21, net earnings margin expanded to 28.46% on revenue of $24.56 billion, a 9.1% year‐over‐year increase, while earnings per share matched street forecasts at $2.46. Return on equity reached 33.34%, and guided full‐year EPS between $11.43 and $11.63 suggests mid‐single‐digit growth over consensus. The company also declared a quarterly dividend of $1.30 per share, payable March 10 to shareholders of record February 24, implying a 2.3% yield and a payout ratio near 47%. Investors will watch leverage metrics—current ratio 1.07, quick ratio 0.80 and debt‐to‐equity 0.50—to assess balance sheet flexibility for further shareholder returns or R&D investment.